Argent BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Argent BioPharma şirketinin toplam hissedar öz sermayesi A$-5.8M ve toplam borcu A$8.7M olup, bu da borç-öz sermaye oranını -149% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$10.8M ve A$16.6M dir.

Anahtar bilgiler

-149.0%

Borç/özkaynak oranı

AU$8.68m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$702.87k
Eşitlik	-AU$5.82m
Toplam yükümlülükler	AU$16.61m
Toplam varlıklar	AU$10.79m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: H5O0 negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: H5O0 şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: H5O0 negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: H5O0 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: H5O0 son raporlanan serbest nakit akışına göre 1 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: H5O0 serbest nakit akışı tahminlerine göre 1 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Argent BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Recent updates

Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Co-Founder recently bought €1.0m worth of stock

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Less than half of directors are independent

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

Less than half of directors are independent

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System

Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences

MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product

Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021

MGC Pharmaceuticals Ltd Announces Further Results from the Phase II Clinical and Preclinical Studies on ArtemiC(TM)

Joint Company Secretary has left the company